Over the last few years, Curetis has created a down-to-earth and continuous success story. It all began with the Unyvero product idea and progressed through the development and approval procedure towards tapping into the international medical technology markets. From the outset, the company has impressed with its high awareness of quality combined with a strong pioneering spirit and the simple claim: "We care for diagnostics". This success was due, in no small part, to the outstanding engineering capabilities and molecular and microbiological expertise of both our investors and our customers and partners.
Curetis' growth potential lies, on the one hand, in developing and expanding the world's national markets and, on the other hand, in extending the Unyvero system with a continuous stream of new cartridges for additional infectious diseases.
Curetis to Present at Key Investor and Scientific Conferences in the Fourth Quarter 2017
MGI and Curetis to Collaborate on NGS-based Infectious Disease Diagnostics
CRIOAC, 3ème Congrès des Centres de Référence des Infections Ostéo-Articulaires Complexes - Tours, France - October, 19 to 20, 2017
Deutscher Kongress für Orthopädie und Unfallchirurgie - Berlin, Germany - October 23 to 27, 2017